Results 11 to 20 of about 244,568 (170)

A Novel Intrauterine Device for the Spatio-Temporal Release of Norethindrone Acetate as a Counter-Estrogenic Intervention in the Genitourinary Syndrome of Menopause [PDF]

Pharmaceutics
The genitourinary syndrome of menopause (GSM) is a widely occurring condition affecting millions of women worldwide. The current treatment of GSM involves the use of orally or vaginally administered estrogens, often with the risk of endometrial ...
Ahmed Abdelgader, Mershen Govender, Pradeep Kumar, Yahya E. Choonara   +3 more
doaj   +2 more sources

A Matched Case-Control Study Examining the Association Between Exposure to Depot Medroxyprogesterone Acetate and Cerebral Meningioma Using an Active Comparator [PDF]

Current Oncology
The recent literature has reported an increased association between the use of depot medroxyprogesterone acetate (dMPA) and cerebral meningioma (CM). Prior studies have been limited in generalizability and did not use an active comparator as a control ...
Russell Griffin, Rebecca Arend
doaj   +2 more sources

Evaluation of pharmacokinetic interactions between long‐acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084 [PDF]

Journal of the International AIDS Society
Introduction HPTN 084 found that long‐acting cabotegravir (CAB‐LA) was well‐tolerated and significantly reduced the risk of HIV acquisition in women compared to tenofovir disoproxil fumarate/emtricitabine (F/TDF).
Mark A. Marzinke, Brett Hanscom, Daniel Haines, Kimberly K. Scarsi, Yaw Agyei, Estelle Piwowar‐Manning, Craig W. Hendrix, Ryann Gollings, Scott Rose, Carrie Mathew, Ravindre Panchia, Elizabeth Spooner, Nishanta Singh, Peter Bock, Alex R. Rinehart, Susan L. Ford, James F. Rooney, Lydia Soto‐Torres, Myron S. Cohen, Mina C. Hosseinipour, Sinead Delany‐Moretlwe, HPTN 084 Study Team   +21 more
doaj   +2 more sources

Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study

Fertility and Sterility, 2004
OBJECTIVE: To determine the role of an aromatase inhibitor, letrozole, in the treatment of reproductive-age women with endometriosis and associated chronic pelvic pain. DESIGN: Phase 2, open-label, nonrandomized proof-of-concept study.
Serdar Bulun, Bilgin Gürates
exaly   +2 more sources

Bone mineral density with elagolix plus add-back therapy in women with heavy menstrual bleeding and uterine fibroids: open-label and post-treatment results of a 60-month phase 3 trialAJOG Global Reports at a Glance [PDF]

AJOG Global Reports
Background: The gonadotropin-releasing hormone antagonist elagolix (ELA) plus hormonal add-back (+AB) therapy reduces menstrual blood loss in women with heavy menstrual bleeding (HMB) associated and uterine fibroids.
Vicki L. Schnell, MD, Liesl K. Bredeson, MD, Eric Brown, MD, Anna Chan, PharmD, James Thomas, MS, James Simon, MD, Michael C. Snabes, MD, PhD   +6 more
doaj   +2 more sources

Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial [PDF]

International Journal of Women's Health
Andrea S Lukes,1 Roberta Venturella,2 Krzysztof Dynowski,3 Rachel B Wagman,4 Julie S Perry,4 Yi Zhong,5 Viatcheslav G Rakov,6 Sylvia Mechsner,7 Neil P Johnson81Carolina Woman’s Research and Wellness Center, Durham, NC, USA; 2Department of Clinical and ...
Lukes AS, Venturella R, Dynowski K, Wagman RB, Perry JS, Zhong Y, Rakov VG, Mechsner S, Johnson NP   +8 more
doaj   +2 more sources

Treatment of Endometriosis and Chronic Pelvic Pain with Letrozole and Norethindrone Acetate [PDF]

Medical Journal Armed Forces India, 2010
Endometriosis is encountered in 7-10% of actively menstruating women, with a suspected prevalence as high as 22% in asymptomatic women. It is an important cause of chronic pelvic pain. The aim of this study was to evaluate the efficacy and safety of letrozole in combination with norethindrone acetate and calcium in the management of endometriosis ...
Chawla S.
openaire   +3 more sources

Bioequivalence of a Fixed-Dose Combination of Relugolix, Estradiol, and Norethindrone Acetate: An Open-Label, Randomized, Fully Replicate Crossover Study in Healthy Postmenopausal Women Under Fasting Conditions. [PDF]

Clin Pharmacol Drug Dev
Abstract Uterine fibroids are the most common benign gynecological tumors, often causing heavy menstrual bleeding (HMB), anemia, and impaired quality of life. A fixed‐dose combination (FDC) of relugolix (40 mg), estradiol (1 mg), and norethindrone acetate (0.5 mg) was developed to address these limitations.
Kotadia R, Kumar S, Khuroo A, Dharmadhikari S, Shahi P, Narayana GNVSS, Reyar S.   +6 more
europepmc   +2 more sources

The effects of starter feed on intestinal fungi and non-targeted metabolomics of blood in calf yaks [PDF]

BMC Microbiology
Yaks are the primary ruminant on the Qinghai-Xizang Plateau, playing a central role in the livelihoods of local farmers and herders. They serve as a vital source of food, clothing, shelter, and transportation in the region.
Hongzhuang Wang, Duojie Qingni, Qing He, Zhandui Pingcuo, Nan Jiang, Yanbin Zhu, Qiang Zhang, Guifang Liu, Guangming Sun, Yangji Cidan, Faisal Ayub Kiani, Dunzhu Luosang, Wangdui Basang   +12 more
doaj   +2 more sources

Considerations for Menstrual Suppression in Patients With Hematologic Malignancies. [PDF]

Pharmacotherapy
ABSTRACT Patients who menstruate during treatment for hematologic malignancies have a higher risk of heavy vaginal bleeding due to thrombocytopenia caused by malignancy and myelosuppressive chemotherapy. Heavy menstrual bleeding is associated with significant morbidity in this patient population, and menstrual suppression is a standard of supportive ...
Veeravalli S, Schepers A, Benitez LL, Fraga MS.   +3 more
europepmc   +2 more sources